BeStock  
Stocks › MESO

Mesoblast MESO

US equityMarket cap rank #2839Biotechnology
$14.22 +$0.14 (+0.99%)
Pre-market · Oct 6, 7:10 am ET · After hours $14.16 -0.42%
Open$14.09
Prev close$14.08
Day range$13.97 – $14.30
Volume181.1K
Market cap$1.85B
P/E (TTM)–
Dividend yield–

MESO Stock News

Headlines matching Mesoblast or the MESO ticker, most recent first.

  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $35Market news · 26 Sep 2026
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $39Market news · 27 Aug 2026
  • Mesoblast (MESO.US) will release its earnings report after the market close on August 26.Market news · 24 Aug 2026
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $35Market news · 10 Apr 2026
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $35Market news · 2 Mar 2026
  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $30Market news · 6 Sep 2025
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $24Market news · 10 Sep 2025
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $24Market news · 7 Feb 2025
  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $35Market news · 9 Oct 2025
  • Maxim Group Upgrades Mesoblast(MESO.US) to Buy Rating, Cuts Target Price to $12Market news · 24 Sep 2024
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Announces Target Price $11Market news · 29 Aug 2024
  • Piper Sandler Upgrades Mesoblast(MESO.US) to Buy RatingMarket news · 24 Jul 2024
  • Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $15Market news · 21 Dec 2024
  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $30Market news · 21 Dec 2024
  • Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $18Market news · 6 Nov 2024

Discussion

No comments yet — be the first to weigh in on MESO.

Leave a comment

Scroll to Top